Byetta Losing Out To Novo's Victoza

Clinical data supporting the ability of type-2 diabetes drug Byetta to address the unmet need of glucose control with potential weight loss quickly became a winning narrative for Amylin Pharmaceutical (AMLN-$$20.08) and its marketing partner Eli Lilly (LLY-$37.77). The GLP-1 agonist became the fourth most-prescribed branded product for type 2-diabetes — after Actos, Avandia and Lantus — within 18 months of its June 2005 launch.

Prescription momentum swung away from the injection med after reports began to surface of a link between Byetta use and altered kidney function. Throw in concerns of pancreatic inflammation - U.S. sales for the GLP-1 agonist peaked in 2008 at $678.5 million.

The number of patients treated worldwide with Byetta dropped from 470,000 in 2007 to 440,000 in 2009, according to data obtained by Wolters Kluwer.

Launched in early 2010, Novo Nordisk’s (NVO-$90.37) GLP-1 agonist Victoza, has already passed Byetta in new patient starts …. Why? Continue Reading ….

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.